Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-10-01
2011-10-25
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S327000, C514S422000, C514S424000, C546S290000, C548S543000
Reexamination Certificate
active
08044069
ABSTRACT:
The present application relates to calcium channel inhibitors containing compounds of formula (I)wherein Ar1, Ar2, L1, L2, n, R1, R4, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
REFERENCES:
patent: 5229388 (1993-07-01), Hrib et al.
patent: 2005/0148587 (2005-07-01), Fraser et al.
patent: WO-0059882 (2000-10-01), None
patent: WO-2007125398 (2007-11-01), None
patent: WO-2008043533 (2008-04-01), None
patent: WO-2008046527 (2008-04-01), None
Schafer et al. Drug Discovery Today, vol. 13, p. 913 (2008).
Horig et al. Journal of Translational Medicine, vol. 2, p. 44 (2004).
Angeli F. et al., “Calcium channel blockade to prevent stroke in hypertension,” American Journal of Hypertension, 2004, vol. 17 (9), pp. 817-822.
Arulmoshi D. K. et al., “Migraine: Current concepts and emerging therapies,” Vascular Pharmacology, 2005, vol. 43, pp. 176-187.
Bao J. et al., “Differences in Ca2+ channels governing generation of miniature and evoked excitatory synaptic currents in spinal laminae I and II,” J Neurosci, 1998, vol. 18 (21), pp. 8740-8750.
Barberis M. et al., “Systhesis of a novel series of 4,4-disubstituted 2,3,4,7—tetrahydroazepines,” Tetrahedron Letters, 2005, vol. 146, pp. 4847-4850.
Barnette Mary S. et al., “Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for (3H)rolipram binding,” Biochemical Pharmacology, 1996, vol. 51, pp. 949-956.
Barone F. C. et al., “SB 201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischemia in rats and mice,” Stroke, 1995, vol. 26, pp. 1683-1690.
Bell, “Cell specific alternative splicing increases calcium channel density in the pain pathway,” Neuron, 2004, vol. 41 (1), pp. 127-138.
Berge S. M. et al., “Describe pharmaceutically acceptable salts in detail,” J. Pharmaceutical Sciences, 1977, vol. 66, pp. 1.
Beuckmann C. et al., “N-type calcium channel alpha1B subunit(Cav2.2) knock-out mice display hyperactivity and vigilance state differences,” J. Neurosci, 2003, vol. 23 (17), pp. 6793-6797.
Bhatia R. et al., “Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbP channel-mediated cellular toxicity,” FASEB J, 2000, vol. 14 (9), pp. 1233-1243.
Bhattacharjee A. et al., “T-Type calcium channels facilitate insulin secretion by enhancing general excitability in the insulin-secreting b-cell line, INS-1,” Endocrinology, 1997, vol. 138 (9), pp. 3735-3740.
Bilici D. et al., “Protective effect of T-type calcium channel blocker in histamine-induced paw inflammation in rat,” Pharmacological Research, 2001, vol. 44 (6), pp. 527-531.
Bowersox S. S. et al. , “Selective N-type neuronal voltage-sensitive calcium channel blocker SNX-111 produced spinal antinociception in rat models of acute persistent and neuropathic pain,” J. Pharmacol. Exp. Ther, 1996, vol. 279 (3), pp. 1243-1249.
Castiglioni et al., “Alternative splicing in the C-terminus of CaV2.2 controls expression and gating of N-type calcium channels,” J. Physiol, 2006, vol. 576 (Pt 1), pp. 119-134.
Cavalli, A. et al., “Multi-target directed ligands to combat neurodegenerative diseases,” J. Med. Chem., 2008, vol. 51 (3), pp. 347-372.
Chaplan S. R. et al., “Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia,” J. Pharmacol. Exp. Ther, 1994, vol. 269 (3), pp. 1117-1123.
Chaplan S. R. et al., “Quantitative assessment of tactile allodynia in the rat paw,” Journal of Neuroscience Methods, 1994, vol. 53, pp. 55-63.
Cizkova, “Localization of N-type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury,” Exp. Brain Res, 2002, vol. 147, pp. 456-463.
Colbourne F. et al., “Continuing postischemic neuronal death in CA1: Influence of ischemia duration and cytoprotective doses of NBQX and SNX-111 in rats,” Stroke, 1999, vol. 30 (3), pp. 662-668.
Croom K. F. et al., “A review of the use of modified-release formulations in the treatment of hypertension and angina pectoris,” Drugs, 2006, vol. 66 (4), pp. 497-528.
Darszon A. et al., “Ion channels in sperm physiology,” Physiological Reviews, 1999, vol. 79 (2), pp. 481-510.
de Filippis A. et al., “Palladium-catalyted [alpha]-arylation of N-protected 2-piperidinones,” Tetrahedron, 2004, vol. 60, pp. 9757-9767.
Dolphin A. C., “A short history of voltage-gated calcium channels,” British Journal of Pharmacology, 2006, vol. 147, pp. S56-S62.
Eliel, E. L. et al., “Stereochemistry of Organic Compounds,” 1994, pp. 119-120, 1206, John Wiley & Sons, Inc. New York.
Evans A. R et al., “Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons,” Brain Res, 1996, vol. 712 (2), pp. 265-273.
Feng Z. P. et al., “Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA,” J. Biol. Chem, 2003, vol. 278 (22), pp. 20171-20178.
Geldenhuys W. J. et al., “Structure-activity relationships of pentacycloundecylamines at the N-methyl-D-aspartate receptor,” Bioorganic and Medicinal Chemistry, 2007, vol. 15, pp. 1525-1532.
Gitlin M., “Treatment-resistant bipolar disorder,” Molecular Psychiatry, 2006, vol. 11, pp. 227-240.
Gladstone J. P. et al., “Current and emerging treatment options for migraine and other primary headache disorders,” Expert Rev. Neurotherapeutics, 2003, vol. 3 (6), pp. 845-872.
Gould R. J. et al., “Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists,” Proc. Natl. Acad. Sci, 1983, vol. 80, pp. 5122-5125.
Gray et al., “Neuronal calcium channels: splicing for optimal performance,” Cell Calcium, 2007, vol. 42 (4-5), pp. 409-417.
Greene T. W. et al., “Protective Groups in Organic Synthesis,” 1999, Ed. 3, John Wiley & Sons, pp. 494-653.
Hatakeyama, “Differential nociceptive responses in mice lacking the alpha1B subunit of N-type Ca2+ channels,” Neuroreport, 2001, vol. 12 (11), pp. 2423-2427.
Heinemann U. et al., “Extracellular free calcium and potassium during paroxysmal activity in the cerebral cortex of the cat,” Brain Res, 1977, vol. 27, pp. 237-243.
Heinke B. et al., “Pre- and postsynaptic contributions of voltage-dependent Ca2+ channels to nociceptive transmission in rat spinal lamina I neurons,” Eur. J. Neurosci, 2004, vol. 19 (1), pp. 103-111.
IUPAC Commission on Nomenclature of Organic Chemistry: Rules for the Nomenclature of Organic Chemistry Section E: Stereochemistry, Pure Appl Chem, 1976, vol. 45, pp. 13-30.
Kim, “Altered nociceptive response in mice deficient in the alpha1B subunit of the voltage-dependent calcium channel,” Mol. Cell. Neurosci, 2001, vol. 18 (2), pp. 235-245.
Levy N. A. et al., “Calcium channel antagonists for the treatment of bipolar disorder,” Bipolar Disorders, 2000, vol. 2 (2), pp. 108-119.
Little H. J. et al., “Calcium channel antagonists decrease the ethanol withdrawal syndrome,” Life Sciences, 1986, vol. 39, pp. 2059-2065.
Liu, “In vivo analysis of voltage-dependent calcium channels,” J. Bioenerg. Biomembr, 2003, vol. 35 (6), pp. 671-685.
Lorton D., “beta-Amyloid-induced IL-1 beta release from an activated human monocyte cell line is calcium- and G-protein-dependent,” Mech Ageing Dev, 1997, vol. 94 (1-3), pp. 199-211.
Lubin M. L. et al., “A nonadherent cell-based HTS assay for N-type calcium channel using calcium 3 dye,” Assay
Bhatia Pramila A.
Doherty George A.
Drizin Irene
Mack Helmut
Perner Richard J.
Abbott & GmbH & Co. KG
Abbott Laboratories
Chu Yong
Michael & Best & Friedrich LLP
Mueller Lisa V.
LandOfFree
Compounds as calcium channel blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds as calcium channel blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds as calcium channel blockers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4294157